Abstract
<h3>To the Editor.</h3> —We have read with interest the excellentArchivesarticle by Dodd et al. After reading this review, one is tempted to believe that the triggering of malignant hyperthermia can be prevented by use of a "safe" anesthetic agent. We, however, have had the disconcerting experience of seeing a phenomenon, to our knowledge not previously reported—development of an episode of malignant hyperthermia after oral pretreatment with dantrolene sodium and administration of an anesthetic agent suggested by most to be nontriggering. Details of this ophthalmic case can be found in<i>Anesthesiology</i>(1981;54:1-2, 73-75). This first reported case of such an occurrence stresses the continued vigilance one must maintain despite following the usual and accepted protocol for patients suspected of having malignant hyperthermia. Other details associated with malignant hyperthermia that we would emphasize are as follows: There may not be any temperature rise in a specific person in whom
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.